相关实验视频

Updated: May 8, 2025

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

加巴丁与普雷加巴林在外科手术期间开始与功能相关:一个向试验仿真研究

Yanfang He¹, Liqian Mo², Juan Li¹

¹Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Frontiers in medicine

|December 25, 2024

概括

与普雷加巴林不同的是,在外科手术期间启动 gabapentin 增加了功能下降和慢性病 (CKD) 的风险. 加巴丁类药物是手术后常见的止痛药.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
药理学药理学是指药理学的学科.
在外科手术期间的医学.

背景情况:

包括 gabapentin 和 pregabalin 在内的 gabapentinoids 在外科手术期间疼痛管理中经常被用作阿片类药物的替代品.
当在手术前后开始时,它们对结局的影响需要进一步调查.

研究的目的:

为了比较在外科手术期间启动 gabapentin 与pregabalin 对不良结局的影响.
评估功能下降,发生慢性病 (CKD) 和医院获得的急性损伤 (AKI) 的风险.

主要方法:

一项使用INSPIRE成年手术患者数据库的回顾性研究.
在 gabapentin 和 pregabalin 发起者之间平衡基线特征的倾向性得分匹配.
考克斯比例危险回归以估计脏结果的危险比率 (HR).

主要成果:

与普雷加巴林相比,开始服用 gabapentin 与功能下降的风险更高 (HR,1.40).
在排除已有CKD的患者后,加巴丁启动也显示发生CKD的风险更高 (HR,1.46).
两组之间没有观察到AKI或住院死亡率的显著差异.

结论:

与pregabalin相比,对 gabapentin的外科手术开始与功能下降和发生CKD的风险增加有关.
这些发现突出了手术患者常用的 gabapentinoids 的潜在的安全性.

关键词:

急性脏损伤急性脏损伤是什么 gabapentin gabapentin 的使用方法功能功能功能在外科手术期间,治疗疼痛.普雷加巴林 (Pregabalin) 是一种药物.

更多相关视频

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

相关概念视频

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...